GSA Capital Partners LLP Acquires 157,989 Shares of Intellia Therapeutics, Inc. $NTLA

GSA Capital Partners LLP increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 210.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 233,080 shares of the company’s stock after buying an additional 157,989 shares during the quarter. GSA Capital Partners LLP’s holdings in Intellia Therapeutics were worth $2,095,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Comerica Bank lifted its position in shares of Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Intellia Therapeutics during the 2nd quarter worth $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $33,000. Finally, Spire Wealth Management bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth $37,000. 88.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on NTLA shares. The Goldman Sachs Group upped their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research report on Tuesday, April 28th. HC Wainwright dropped their price objective on Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Leerink Partners set a $35.00 target price on Intellia Therapeutics in a report on Monday, April 27th. Wells Fargo & Company upped their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada upped their target price on Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $20.25.

Intellia Therapeutics Stock Down 5.9%

Shares of NTLA opened at $11.94 on Wednesday. Intellia Therapeutics, Inc. has a 12-month low of $6.83 and a 12-month high of $28.25. The business has a 50-day simple moving average of $13.59 and a two-hundred day simple moving average of $11.95. The stock has a market cap of $1.67 billion, a PE ratio of -3.37 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the prior year, the firm earned ($1.10) EPS. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -3.35 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.